1. Medtech Insight
  2. >>Business

Exec Chat: Dexcom’s CEO On Meeting New CGM Markets While Scoping Consumer Opportunities

 
• By Marion Webb

In this first of a series of Exec Chats with leaders at major diabetes companies presenting at ADA’s Scientific Sessions 2023, CEO Kevin Sayer discusses Dexcom’s ambitious R&D map to expand into metabolic health and develop innovative new products for diabetes and consumer markets.

American Diabetes Association Annual Meeting 2023: San Diego, California, USA - January 29, 2018: A panoramic morning view of San Diego Marina, surrounded by modern high-rising buildings, at side of San Diego Bay in Marina District of the Downtown.
• Source: Shutterstock

DexCom, Inc. kicked off the American Diabetes Association (ADA) on a bullish note.

The San Diego-based leader in continuous glucose monitoring raised its 2025 revenue targets by $600m to a range of $4.6bn-$5.1bn at its 23 June Investor Day meeting.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

More from Business

Edwards Lifesciences Holds 2025 EPS Outlook Despite Tariff Headwind

 
• By Shubham Singh

The brunt of the tariff exposure stems from Singapore and Costa Rica, which together account for an estimated 70% to 80% of the tariff-related cost burden. Less than 10% of the exposure is tied to China.

Data Finds Capillary Blood Is A Reliable Alternative To Venous Blood For Routine Testing

 
• By Natasha Barrow

A study from Babson Diagnostics published in the peer-reviewed Journal of Applied Laboratory Medicine showed that capillary blood sample volume issues can overcome historical challenges, such as poor quality, through a technique called assay miniaturization.

Inclusive By Design: UK Invites Sponsors To Submit Trial Diversity Plans

 
• By Vibha Sharma

The UK has issued clearer guidance to help drug and medical device sponsors demonstrate how they intend to include a diverse and relevant range of participants in their clinical trials.